Compare SMID & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | AGEN |
|---|---|---|
| Founded | 1960 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.3M | 147.4M |
| IPO Year | 1996 | 1999 |
| Metric | SMID | AGEN |
|---|---|---|
| Price | $30.83 | $3.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 5.9K | ★ 672.7K |
| Earning Date | 04-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 62.76 | ★ 100.00 |
| EPS | ★ 2.36 | 1.02 |
| Revenue | ★ $93,446,000.00 | $42,877,086.00 |
| Revenue This Year | N/A | $107.63 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.06 | ★ $3.33 |
| Revenue Growth | 19.03 | ★ 89.95 |
| 52 Week Low | $25.60 | $2.71 |
| 52 Week High | $43.62 | $7.34 |
| Indicator | SMID | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 47.93 | 42.85 |
| Support Level | $26.74 | $2.93 |
| Resistance Level | $36.74 | $3.26 |
| Average True Range (ATR) | 1.52 | 0.22 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 56.61 | 36.93 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.